Physician
Hematology
Dr. Taofeek K. Owonikoko, MD
|
|
Give Review
Dr. Taofeek K. Owonikoko works in the field of Hematology. Dr. Taofeek K. Owonikoko is a published physician as well. He has 69 publications published. The latest was: Small Cell Lung Cancer: Can recent advances in biology and molecular biology be translated into improved outcomes? Taofeek Owonikoko accepts Medicare payments and is listed with Medicare.gov.
Publications
- Role of race in oncogenic driver prevalence and outcomes in lung adenocarcinoma: Results from the Lung Cancer Mutation Consortium.
- Clinical Validation and Implementation of a Targeted Next-Generation Sequencing Assay to Detect Somatic Variants in Non-Small Cell Lung, Melanoma, and Gastrointestinal...
- Small Cell Lung Cancer: Can recent advances in biology and molecular biology be translated into improved outcomes?
- Biomarkers and targeted systemic therapies in advanced non-small cell lung Cancer.
- Predictors and outcomes of venous thromboembolism in hospitalized lung Cancer patients: A Nationwide Inpatient Sample database analysis.
- Atypical carcinoid tumor of the lung: a surveillance, epidemiology, and end results database Analysis.
- Management patterns and predictors of mortality among US patients with Cancer hospitalized for malignant bowel obstruction.
- Anaplastic Lymphoma kinase (ALK) gene alteration in signet ring cell carcinoma of the gastrointestinal tract.
- GSK3 is required for rapalogs to induce degradation of some oncogenic proteins and to suppress Cancer cell growth.
- Minimize toxicity or preserve efficacy? A delicate trade-off in the management of older patients with lung Cancer.
- A Translational, Pharmacodynamic, and Pharmacokinetic Phase IB Clinical Study of Everolimus in Resectable Non-Small Cell Lung Cancer.
- Bcl2 inhibits recruitment of Mre11 complex to DNA double-strand breaks in response to high-linear energy transfer radiation.
- Phase 1 and pharmacokinetic study of everolimus in combination with cetuximab and carboplatin for recurrent/metastatic squamous cell carcinoma of the head and neck.
- Development and testing of a tool to assess patient preferences for phase I clinical trial participation.
- Post-Operative Radiotherapy (PORT) is Associated with Better Survival in Non-Small Cell Lung Cancer with Involved N2 Lymph Nodes: Results of an Analysis of the Nationa...
- Concurrent therapy with taxane versus non-taxane containing regimens in locally advanced squamous cell carcinomas of the head and neck (SCCHN): a Systematic review.
- Role of Ku70 in deubiquitination of Mcl-1 and suppression of apoptosis.
- Chemoprevention of head and neck Cancer with celecoxib and erlotinib: results of a phase ib and pharmacokinetic study.
- HPV-associated lung Cancers: an international pooled analysis.
- Escalation with overdose control using all toxicities and time to event toxicity data in Cancer Phase I clinical trials.
- Current approaches to the treatment of metastatic Brain tumours.
- Bcl2 induces DNA replication stress by inhibiting ribonucleotide reductase.
- Taxanes: vesicants, irritants, or just irritating?
- E5501: phase II study of topotecan sequenced with etoposide/cisplatin, and irinotecan/cisplatin sequenced with etoposide for extensive-stage small-cell lung Cancer.
- Niclosamide Overcomes Acquired Resistance to Erlotinib through Suppression of STAT3 in Non-Small Cell Lung Cancer.
- Novel Small-Molecule Inhibitors of Bcl-XL to Treat Lung Cancer.
- Acetylated Tubulin (AT) as a Prognostic Marker in Squamous Cell Carcinoma of the Head and Neck.
- Paranasal sinus squamous cell carcinoma incidence and survival based on Surveillance, Epidemiology, and End Results Data, 1973 to 2009.
- The PI3 kinase inhibitor NVP-BKM120 induces GSK3/FBXW7-dependent Mcl-1 degradation, contributing to induction of apoptosis and enhancement of TRAIL-induced apoptosis.
- Upholding the principles of autonomy, beneficence, and justice in phase I clinical trials.
- CHFR Protein Expression Predicts Outcomes to Taxane-Based First Line Therapy in Metastatic NSCLC.
- Phase II Study of Docetaxel in Combination with Everolimus for Second- or Third-Line Therapy of Advanced Non-Small-Cell Lung Cancer.
- Soluble FAS ligand as a biomarker of disease recurrence in differentiated thyroid Cancer.
- A phase 1 Bayesian dose selection study of bortezomib and sunitinib in patients with refractory solid tumor malignancies.
- c-Myc suppression of DNA double-strand break repair.
- The combination of RAD001 and NVP-BKM120 synergistically inhibits the growth of lung Cancer in vitro and in vivo.
- Elevated expression of eukaryotic translation initiation factor 4E is associated with proliferation, invasion and acquired resistance to erlotinib in lung Cancer.
- NNK promotes migration and invasion of lung Cancer cells through activation of c-Src/ PKC?/ FAK loop.
- Statistical learning methods as a preprocessing step for survival analysis: evaluation of concept using lung Cancer data.
- Oncogenic Ras and B-Raf positively regulates death receptor 5 expression through co-activation of ERK and JNK signaling.
- Rapamycin Induces Bad Phosphorylation in Association with Its Resistance to Human Lung Cancer Cells.
- Augmentation of NVP-BEZ235's antiCancer activity against human lung Cancer cells by blockage of autophagy.
- Human immunodeficiency virus-associated lung Cancer in the era of highly active antiretroviral therapy.
- Lung Cancer: New biological insights and recent therapeutic advances.
- The Combination of RAD001 and NVP-BEZ235 Exerts Synergistic AntiCancer Activity against Non-Small Cell Lung Cancer In Vitro and In Vivo.
- Lung Cancer in the elderly: what's age got to do with it?
- Phase 1 and pharmacokinetic study of everolimus, a mammalian target of rapamycin inhibitor, in combination with docetaxel for recurrent/refractory nonsmall cell Lung c...
- Maintenance therapy for advanced non-small cell lung Cancer: current status, controversies, and emerging consensus.
- Vorinostat increases carboplatin and paclitaxel activity in non-small-cell lung Cancer cells.
- Preoperative therapy for early-stage NSCLC: opportunities and challenges.
- The role of cetuximab in the management of non-small-cell lung Cancer.
- The role of targeted agents in the treatment of elderly patients with non-small cell lung Cancer (NSCLC).
- Small cell lung Cancer in elderly patients: a review.
- Lung Cancer in elderly patients: an analysis of the surveillance, epidemiology, and end results database.
- In vivo investigation of estrogen regulation of Adrenal and renal angiotensin (AT1) receptor expression by PET.
- Small-molecule Bax agonists for Cancer therapy.
- Interactive Software "Isotonic Design using Normalized Equivalent Toxicity Score (ID-NETS©TM)" for Cancer Phase I Clinical Trials.
- Real-World Effectiveness of Systemic Agents Approved for Advanced Non-Small Cell Lung Cancer: A SEER-Medicare Analysis.
- Comparison of (+)-(11)C-McN5652 and (11)C-DASB as serotonin transporter radioligands under various experimental conditions.
- IntratumOral genetic heterogeneity in Barrett adenocarcinoma.
- Comparative Analysis of basaloid and typical squamous cell carcinoma of the oesophagus: a molecular biological and immunohistochemical study.
- ColoRectal neoplasms: a retrospective study.
- Minimal progress, potential promise in small-cell lung Cancer.
- Oncogenic role of EAPII in lung Cancer development and its activation of the MAPK-ERK pathway.
- Gender and ethnic disparities in incidence and survival of squamous cell carcinoma of the Oral tongue, base of tongue, and tonsils: a surveillance, epidemiology and en...
- What is the role of maintenance therapy in the treatment of non-small cell lung Cancer?
- Gemtuzumab therapy for isolated extramedullary AML relapse following allogeneic stem-cell transplant.
- Positron emission tomography imaging of the serotonin transporter in subjects with a history of alcoholism.
Schools
University Of Ife Faculty Of Health Sciences
Graduate Hospital
Lagos University Teaching Hospital
University Of Pittsburgh Med Center
Procedures Preformed
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
Education
-
University of Pittsburgh Medical Center -
Obafemi Awolowo College of Health Sciences, Ogun State University
Hospital
-
Emory University Hospital
Drug Facts
| NPI NUMBER | 1578770871 | |
| NPPES Provider LastName | OWONIKOKO | |
| NPPES Provider FirstName | TAOFEEK | |
| NPPES Provider ZIPCode | 152153205 | |
| NPPES Provider State | PA | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 424.0 | |
| Distinct Opioid Count | 4.0 | |
| Opioid Claim Count | 85.0 | |
| Percent Opioid Claims | 20.05 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1578770871 |
| Last Name Of The Provider | OWONIKOKO |
| First Name Of The Provider | TAOFEEK |
| View All |
Similar Doctors
|
|
Dr. James R. Eckman, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Anna J. Janss, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Bradley C. Carthon, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Vamsi K. Kota, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Dong M. Shin, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Jacques Galipeau, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Hima B. Lingam, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mauricio Zapata, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Melvin R. Moore, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Rajasree P. Chowdry, MD |
|
|
Dr. Wassim M. McHayleh, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Duc Q. Tran Jr., MD |
|
|
Linda Ballard, CPNP |
|
|
Dr. Shuang Y. Zhang, MD |